Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Gene expression profiling has been studied in the prognostication of multiple myeloma for over a decade, Usmani says. Now, different tools are making their way to the clinical setting, one of which is the MMprofiler.
Findings of the VTD arm of the phase III Gimema-MMY-3006 study were presented at the 2017 ASH Annual Meeting. This study investigated the MMprofiler with SKY92 combined with ISS to identify high- and low-risk patients with multiple myeloma.
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More